Health Care Costs

Latest California Healthline Stories

As Congress Wrestles With Plans to Expand Medicare, Becerra Says Any One Will Do

In an interview for KHN’s “What the Health?” podcast, HHS Secretary Xavier Becerra says the administration is eager for Congress to make changes to Medicare that will provide more benefits and make more older adults eligible for the program. He also said a priority will be making permanent the enhanced premium subsidies for Affordable Care Act marketplace plans.

Drugmakers’ Spending on Stock, Dividends and Executive Pay Exceeds Research, Democrats Say

The pharmaceutical industry argues that large profits are needed to fund extensive research and innovation. But Democrats on the House Oversight and Reform Committee, seeking to bolster their effort to let Medicare negotiate drug prices, say major drug companies plow more of their billions in earnings back into propping up their stock and enriching executives and shareholders.

KHN’s ‘What the Health?’: Un-Trumping the ACA

The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act, in an effort to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive new drug that might or might not slow the progression of Alzheimer’s disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of The Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”

States Step Up Push to Regulate Pharmacy Drug Brokers

In an ongoing effort to control prescription drug costs, states are targeting the companies that mediate deals among drug manufacturers, health insurers and pharmacies. The pharmacy benefit managers say they negotiate lower prices for patients, yet the nitty-gritty occurs largely behind a curtain that lawmakers are trying to pull back.